High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
Ralph TayyarLisa Kanata WongAlex DahlenElaine ShuSuchitra PandeyAnne Y LiuPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2023)
CCP is a safe, globally available treatment for immunocompromised patients with COVID-19. Mortality was lower in our cohort than that of COVID-19 patients with similar immunocompromising conditions. Post-vaccine CCP with very high titers should be prioritized for study in immunocompromised patients. Post-vaccine CCP has the potential to keep pace with new variants by overcoming mutations at sufficiently high titer.
Keyphrases
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- sars cov
- prognostic factors
- intensive care unit
- cardiovascular disease
- patient reported outcomes
- dna methylation
- risk factors
- copy number
- cardiovascular events
- patient reported
- smoking cessation
- acute respiratory distress syndrome
- mechanical ventilation
- human health